LLPC Associated studies

Open studies

Short name BELINDA (CCTL019H2301)
Study title Tisagenlecleucel versus standard of care in adult patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma: A randomized, open label, phase III trial
Status Open
Participants The study is open at AMC and UMCUtrecht
Study docs

Study flow and eligibility criteria

 

Short name

TRANSFORM (Celgene JCAR017-BCM-003)
Study title A global randomized multicenter phase 3 trial to compare the efficacy and safety of JCAR017 (Car-T-cell) to standard of care (autologous SCT) in adult subjects with high-risk, transplant-eligible relapsed or refractory aggressive B-cell non-Hodgkin lymphomas
Status Open
Participants The study is open at Erasmus MC (p.lugtenburg@erasmusmc.nl; p.mutsaers@erasmusmc.nl;
researchverpleegkundige@erasmusmc.nl)
Study docs In- and exclusion criteria

 

Short name ACT15320
Study title A Phase 1/2 open-label, multi-center, safety, preliminary efficacy and pharmacokinetic (PK) study of isatuximab in combination with other anti-cancer therapies in participants with lymphoma.
Status Open
Participants Open at MUMC

 

Short name TRANSCEND WORLD (Celgene JCAR017-BCM-001)
Study title A phase 2, single-arm, multi-cohort, multicenter trial to determine the efficacy and safety of JCAR017 (CAR-T-cell) in adult subjects with aggressive B-Cell non-Hodgkin lymphoma.
Status Open
Participants The study is open at Erasmus MC (p.lugtenburg@erasmusmc.nl; p.mutsaers@erasmusmc.nl; researchverpleegkundigehematologie@erasmusmc.nl).
Study docs

Additional inclusion and exclusion criteria
Please inform first if a slot is available for the different cohorts!

 

Short name GCT3013-01
Study title A phase 1-2, open-label, dose-escalation and expansion trial of GEN3013 (bispecific antibody CD20xCD3, epcoritamab) in patients with relapsed, progressive or refractory B-Cell lymphoma.
Status Open
Participants The study is open at Erasmus MC (p.lugtenburg@erasmusmc.nl; p.mutsaers@erasmusmc.nl;
researchverpleegkundige@erasmusmc.nl); VUMC (m.chamuleau@amsterdamumc.nl; hematol@amsterdamumc.nl), UMCU (r.mous@umcutrecht.nl; hemat-research@umcutrecht.nl) and MUMC (marjolein.vander.poel@mumc.nl)
Study info The study is in the expansion phase, part 1. Patients with relapse or refractory DLBCL or Follicular lymphoma (grade 1-3A) may be included, after 2 prior lines of therapy
Study docs  In- and exclusion criteria
Short name CDK9
Study title A Phase 1, Open-Label, Multicentre, Non-Randomized Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of AZD4573, a Potent and Selective CDK9 Inhibitor, in Subjects with Relapsed or Refractory Haematological Malignancies.
Status Open
Participants The study is open in AMC and the Antonius Hospital Nieuwegein
Study docs Eligibility criteria
Short name EDO-S101-1001
Study title Phase 1 study to investigate the safety, pharmacokinetic profiles and efficacy of EDO-S101 (tinostamustine), a first-in-class alkylating histone deacetylase inhibition (HDACi) fusion molecule in relapsed/refractory hematological malignancies.
Status Open
Particpants

The study is open at Erasmus MC (p.lugtenburg@erasmusmc.nl; p.mutsaers@erasmusmc.nl;
researchverpleegkundigehematologie@erasmusmc.nl) and VUMC (j.zijlstra@amsterdamumc.nl; hematol@amsterdamumc.nl).
The study will also open at LUMC

Study info

The study is in stage 2 = expansion phase.
Cohort 2: rr Hodgkin lymphoma after ≥ 3 prior lines therapy
Cohort 3: rr PTCL-NOS, AITL, ALCL, after ≥ 1 prior lines therapy
Cohort 4: rr CTCL (MF; SS), ≥ 1 and ≤ 4 prior lines of systemic therapy
Cohort 5: rr T-PLL after ≤ 2 prior lines of therapy or ineligible for alemtuzumab

Study docs  In- and exclusion criteria

 


 

Planned trials

 

Short name CMAK638X2101
Study title A phase I/II, multicenter, open-label study of MAK683 in adult patients with advanced malignancies, hematological malignancies include relapsed or refractory DLBCL or FL with or without EZH2 mutation and relapsed or refractory T-cell lymphoma
Status Planned

 

Short name Amgen 20150290
Study title Phase 1b/3 study with blinatumumab and pembrolizumab treatment in 3th line DLBCL.
Status Planned
Participants The study will open at Erasmus MC, VUMC, LUMC, St Antonius Nieuwegein and UMCN

 

Short name NP39461
Study title Open-label, dose escalation/expansion phase IB study to evaluate the safety, pharmacokinetics, and clinical activity of the combination of RO6870810 and venetoclax, with or without rituximab, in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
Status Planned
Study docs Protocol synopsis
Eligibility criteria
Up